{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:08:29Z","timestamp":1781719709341,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To assess the clinical value of [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluoroethyl-L-tyrosine PET ([\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET) correlated with MRI in patients with functioning pituitary adenoma (FPA) with negative or equivocal conventional MRIs during diagnosis, persistent disease and recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective observational cohort study of 34 patients with FPAs who underwent a total of 37 [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PETs (Cushing\u2019s disease:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919, acromegaly:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914, prolactinoma:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093, and TSH producing adenoma:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091) between January 2022 and April 2025. The clinical performance was assessed in the surgically treated cohort, using confirmative histopathology and\/or postoperative remission as reference standard.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET identified a single lesion in 28 scans (76%), two lesions in 1 scan (3%), and no lesion in 8 scans (22%). [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET and MRI were concordant positive in 14\/37 scans, concordant negative in 1\/37, discordant MRI+\/[\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET\u2009+\u2009different location in 2\/37, discordant MRI-\/[\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET\u2009+\u2009in 8\/37, discordant MRI+\/[\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET- in 7\/37 and partly concordant in 5\/37 scans. In 14 cases surgery resulted in confirmative histopathology and\/or postoperative remission, 12 of those had a positive [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET. In 6 cases surgery did not result in confirmative histopathology and\/or postoperative remission, of whom 5 had a positive [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET. Overall, the sensitivity was 86% and the positive predictive value 71%. In three patients with acromegaly, [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET was able to localize a lesion, despite biochemical control under continued somatostatin analogue treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET enhances lesion detection and improves personalized treatment in patients with FPA and negative or equivocal conventional MRIs throughout the disease course. Consensus on the timing of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FET-PET with respect to medication and biochemical status is warranted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-025-01634-w","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:27:42Z","timestamp":1772886462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The clinical value of [18F]-fluoro-ethyl-L-tyrosine PET ([18F]FET-PET) correlated with MRI in patients with functioning pituitary adenomas: an observational cohort study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4912-3616","authenticated-orcid":false,"given":"Loren S.","family":"van der Hoeven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1854-2929","authenticated-orcid":false,"given":"Siebren G.","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-7933","authenticated-orcid":false,"given":"Tessa","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2741-7975","authenticated-orcid":false,"given":"Eva A.M.","family":"Heshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0130","authenticated-orcid":false,"given":"Miou S.","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-3770","authenticated-orcid":false,"given":"Eleonora","family":"Aronica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-8070","authenticated-orcid":false,"given":"Jantien","family":"Hoogmoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-9866","authenticated-orcid":false,"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-4233","authenticated-orcid":false,"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-5140","authenticated-orcid":false,"given":"Dirk Jan","family":"Stenvers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"2","key":"1634_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1210\/jc.2012-3362","volume":"98","author":"L \u00d3nnestam","year":"2013","unstructured":"\u00d3nnestam L, Berinder K, Burman P, Dahlqvist P, Engstr\u00f6m BE, Wahlberg J et al (2013) National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 98(2):626\u201335","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1634_CR2","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40618-022-01754-1","volume":"45","author":"G Giuffrida","year":"2022","unstructured":"Giuffrida G, Crisafulli S, Ferra\u00f9 F, Fontana A, Alessi Y, Calapai F et al (2022) Global cushing\u2019s disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest 45(6):1235\u20131246","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1634_CR3","doi-asserted-by":"publisher","first-page":"102856","DOI":"10.1016\/j.arcmed.2023.102856","volume":"54","author":"J Kerbel","year":"2023","unstructured":"Kerbel J, Cano-Zaragoza A, Espinosa-Dorado R, de la Garc\u00eda Torre KE, Mercado M (2023) Real world data on the epidemiology, diagnosis, and treatment of Acromegaly: a registries-based approach. Arch Med Res 54(6):102856","journal-title":"Arch Med Res"},{"issue":"2","key":"1634_CR4","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"1634_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000351007","volume":"2","author":"P Beck-Peccoz","year":"2013","unstructured":"Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL (2013) 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2(2):76\u201382","journal-title":"Eur Thyroid J"},{"issue":"12","key":"1634_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u201375","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1634_CR7","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr., Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u201351","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1634_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol 19(12):722\u201340","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1634_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM et al (2020) Surgery as a viable alternative First-Line treatment for prolactinoma Patients. A systematic review and Meta-Analysis. J Clin Endocrinol Metab 105(3):e32\u201341","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1634_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00330-004-2531-x","volume":"15","author":"JF Bonneville","year":"2005","unstructured":"Bonneville JF, Bonneville F, Cattin F (2005) Magnetic resonance imaging of pituitary adenomas. Eur Radiol 15(3):543\u2013548","journal-title":"Eur Radiol"},{"issue":"3","key":"1634_CR11","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/foc.2007.23.3.4","volume":"23","author":"J Jagannathan","year":"2007","unstructured":"Jagannathan J, Sheehan JP, Jane JA Jr. (2007) Evaluation and management of Cushing syndrome in cases of negative sellar magnetic resonance imaging. Neurosurg Focus 23(3):E3","journal-title":"Neurosurg Focus"},{"issue":"3","key":"1634_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1046\/j.1365-2265.1998.00541.x","volume":"49","author":"A Tabarin","year":"1998","unstructured":"Tabarin A, Laurent F, Catargi B, Olivier-Puel F, Lescene R, Berge J et al (1998) Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of cushing\u2019s disease. Clin Endocrinol (Oxf) 49(3):293\u2013300","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1634_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00330-015-3809-x","volume":"26","author":"AA de Rotte","year":"2016","unstructured":"de Rotte AA, Groenewegen A, Rutgers DR, Witkamp T, Zelissen PM, Meijer FJ et al (2016) High resolution pituitary gland MRI at 7.0 tesla: a clinical evaluation in cushing\u2019s disease. Eur Radiol 26(1):271\u2013277","journal-title":"Eur Radiol"},{"issue":"8","key":"1634_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00234-020-02431-x","volume":"62","author":"V Patel","year":"2020","unstructured":"Patel V, Liu CJ, Shiroishi MS, Hurth K, Carmichael JD, Zada G et al (2020) Ultra-high field magnetic resonance imaging for localization of corticotropin-secreting pituitary adenomas. Neuroradiology 62(8):1051\u20131054","journal-title":"Neuroradiology"},{"issue":"5","key":"1634_CR15","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.55730\/1300-0144.5500","volume":"52","author":"ET Durmu\u015f","year":"2022","unstructured":"Durmu\u015f ET, Atmaca A, Uzunkaya F, \u00c7olak R, Durmu\u015f B (2022) The lateralization accuracy of inferior petrosal sinus sampling in cushing\u2019s disease: experiences of a tertiary center. Turk J Med Sci 52(5):1600\u20131608","journal-title":"Turk J Med Sci"},{"issue":"2","key":"1634_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cen.13505","volume":"88","author":"M Feng","year":"2018","unstructured":"Feng M, Liu Z, Liu X, Zhang X, Bao X, Yao Y et al (2018) Tumour lateralization in cushing\u2019s disease by inferior petrosal sinus sampling with Desmopressin. Clin Endocrinol (Oxf) 88(2):251\u2013257","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1634_CR17","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1210\/jc.2012-3943","volume":"98","author":"JJ Wind","year":"2013","unstructured":"Wind JJ, Lonser RR, Nieman LK, DeVroom HL, Chang R, Oldfield EH (2013) The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with cushing\u2019s disease. J Clin Endocrinol Metab 98(6):2285\u20132293","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1634_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s007010200064","volume":"144","author":"P Kremer","year":"2002","unstructured":"Kremer P, Forsting M, Ranaei G, W\u00fcster C, Hamer J, Sartor K et al (2002) Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir (Wien) 144(5):433\u201343","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"1634_CR19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s11102-021-01160-5","volume":"24","author":"S Berkmann","year":"2021","unstructured":"Berkmann S, Roethlisberger M, Mueller B, Christ-Crain M, Mariani L, Nitzsche E et al (2021) Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET\/MRI. Pituitary 24(6):878\u201386","journal-title":"Pituitary"},{"issue":"4","key":"1634_CR20","doi-asserted-by":"publisher","first-page":"M107\u201320","DOI":"10.1530\/EJE-15-0616","volume":"173","author":"O Koulouri","year":"2015","unstructured":"Koulouri O, Steuwe A, Gillett D, Hoole AC, Powlson AS, Donnelly NA et al (2015) A role for 11C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome. Eur J Endocrinol 173(4):M107\u201320","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1634_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/ejendo\/lvae028","volume":"190","author":"L Haberbosch","year":"2024","unstructured":"Haberbosch L, MacFarlane J, Koulouri O, Gillett D, Powlson AS, Oddy S et al (2024) Real-world experience with 11\u00a0C-methionine positron emission tomography in the management of acromegaly. Eur J Endocrinol 190(4):307\u2013313","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1634_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11102-022-01229-9","volume":"25","author":"WA Bashari","year":"2022","unstructured":"Bashari WA, van der Meulen M, MacFarlane J, Gillett D, Senanayake R, Serban L et al (2022) (11)C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. Pituitary 25(4):573\u201386","journal-title":"Pituitary"},{"issue":"4","key":"1634_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11102-022-01230-2","volume":"25","author":"LEH Bakker","year":"2022","unstructured":"Bakker LEH, Verstegen MJT, Ghariq E, Verbist BM, Schutte PJ, Bashari WA et al (2022) Implementation of functional imaging using (11)C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary 25(4):587\u2013601","journal-title":"Pituitary"},{"issue":"1","key":"1634_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13550-022-00899-7","volume":"12","author":"D Gillett","year":"2022","unstructured":"Gillett D, Senanayake R, MacFarlane J, van der Meulen M, Koulouri O, Powlson AS et al (2022) Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction. EJNMMI Res 12(1):26","journal-title":"EJNMMI Res"},{"issue":"5","key":"1634_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-16-0639","volume":"175","author":"O Koulouri","year":"2016","unstructured":"Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS et al (2016) Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. Eur J Endocrinol 175(5):485\u201398","journal-title":"Eur J Endocrinol"},{"issue":"3\u20134","key":"1634_CR26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.wneu.2013.11.011","volume":"82","author":"S Rodriguez-Barcelo","year":"2014","unstructured":"Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-Moreno L, Arraez-Sanchez M (2014) Clinical usefulness of coregistered 11 C-methionine positron emission tomography\/3-T magnetic resonance imaging at the follow-up of acromegaly. World Neurosurg 82(3\u20134):468\u2013473","journal-title":"World Neurosurg"},{"issue":"6","key":"1634_CR27","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3171\/2023.5.JNS23179","volume":"139","author":"A Ishida","year":"2023","unstructured":"Ishida A, Kaneko K, Minamimoto R, Hotta M, Inoshita N, Takano K et al (2023) Clinical decision-making based on 11\u00a0C-methionine PET in recurrent cushing\u2019s disease with equivocal MRI findings. J Neurosurg 139(6):1671\u20131680","journal-title":"J Neurosurg"},{"key":"1634_CR28","doi-asserted-by":"crossref","unstructured":"Furnica RM, Devuyst F, Mathey C, Constantinescu SM, De Herdt C, Alexopoulou O et al (2025) Diagnostic value of 11\u00a0C-Methionine PET-CT imaging in persistent or recurrent Cushing\u2019s disease after surgery. J Clin Endocrinol Metab","DOI":"10.1210\/clinem\/dgaf047"},{"issue":"2","key":"1634_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00259-005-1882-0","volume":"33","author":"BN Tang","year":"2006","unstructured":"Tang BN, Levivier M, Heureux M, Wikler D, Massager N, Devriendt D et al (2006) 11\u00a0C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging 33(2):169\u2013178","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1634_CR30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269392","author":"A Flaus","year":"2025","unstructured":"Flaus A, Levigoureux E, Haesebaert J, Briet C, Castinetti F, Cristante J et al (2025) Prospective multicenter evaluation of [(11)C]Methionine PET\/MRI sensitivity compared with MRI for localizing small pituitary neuroendocrine tumor or pituitary adenoma in Cushing disease. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.124.269392","journal-title":"J Nucl Med"},{"issue":"3","key":"1634_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.nucmedbio.2006.01.002","volume":"33","author":"KJ Langen","year":"2006","unstructured":"Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D et al (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33(3):287\u201394","journal-title":"Nucl Med Biol"},{"key":"1634_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082919","author":"TNA Slagboom","year":"2023","unstructured":"Slagboom TNA, Stenvers DJ, van de Giessen E, Roosendaal SD, de Win MML, Bot JCJ et al (2023) Continuing challenges in the definitive diagnosis of Cushing\u2019s disease: a structured review focusing on molecular imaging and a proposal for diagnostic work-up. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12082919","journal-title":"J Clin Med"},{"issue":"5","key":"1634_CR33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.2967\/jnumed.123.266853","volume":"65","author":"IJ Pruis","year":"2024","unstructured":"Pruis IJ, Verburg FA, Balvers RK, Harteveld AA, Feelders RA, Vernooij MW et al (2024) [(18)F]FET PET\/MRI: an accurate technique for detection of small functional pituitary tumors. J Nucl Med 65(5):688\u201392","journal-title":"J Nucl Med"},{"issue":"2","key":"1634_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/cen.15079","volume":"101","author":"LEH Bakker","year":"2024","unstructured":"Bakker LEH, Verstegen MJT, Manole DC, Lu H, Decramer TJM, Pelsma ICM et al (2024) (18)F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly. Clin Endocrinol (Oxf) 101(2):142\u2013152","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1634_CR35","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s11102-024-01430-y","volume":"27","author":"VR van Trigt","year":"2024","unstructured":"van Trigt VR, Bakker LEH, Lu H, Pelsma ICM, Verstegen MJT, van Furth WR et al (2024) Clinical use of [(18)F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants. Pituitary 27(5):614\u201324","journal-title":"Pituitary"},{"issue":"1","key":"1634_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al (2021) A pituitary society update to acromegaly management guidelines. Pituitary 24(1):1\u201313","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01634-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:34:02Z","timestamp":1781638442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01634-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01634-w","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}